Close

More on VERV

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (7.5 Score)

Upcoming Events

- Earnings (5/7/25)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Verve Therapeutics (NQ:VERV)
Delayed: 5.27 +0.49 (10.25%)
Prev. Close $4.78  
Open$4.81 
52 Wk High$ 
52 Wk Low$ 
Day High$5.30 
Day Low$4.78 
P/E N/A  
EPS$ 
Volume2,664,556 

Friends, Peers and Foes (?): PRVCF, STOK, RYTM, SLNO, ABOS (more...)

Apr 17, 2025 05:40 PM Form SCHEDULE 13G/A Verve Therapeutics, Inc. Filed by: BlackRock, Inc.
Apr 15, 2025 08:51 AM BMO Capital Reiterates Outperform Rating on Verve Therapeutics (VERV), PT $30
Apr 15, 2025 07:23 AM Verve Therapeutics (VERV) PT Lowered to $16 at JPMorgan
Apr 15, 2025 07:18 AM Verve Therapeutics (VERV) PT Raised to $24 at Guggenheim
Apr 15, 2025 07:10 AM William Blair on Verve Therapeutics (VERV): 'Heart-2 First Look: Reads as a Clear Win With Clean VERVE-102 Safety'
Apr 15, 2025 06:36 AM Verve Therapeutics (VERV) PT Raised to $39 at Canaccord Genuity
Apr 15, 2025 06:19 AM Verve Therapeutics (VERV) Surges 10pct Premarket on Cantor Upgrade, Bullish Commentary, Updated News
Apr 15, 2025 06:09 AM Goldman Comments on Verve Therapeutics (VERV)
Apr 15, 2025 06:06 AM Jefferies Reiterates Buy Rating on Verve Therapeutics (VERV)
Apr 15, 2025 06:06 AM Cantor Fitzgerald Upgrades Verve Therapeutics (VERV) to Overweight, 'We're Impressed by VERVE-102'
View All Articles

Entities mentioned with VERV

View All Entities